US EPA

2725354 

Journal Article 

Effect of amlodipine on insulin secretion, glucose, lipid profile and urinary albumin excretion in patients with mild hypertension and non-insulin-dependent diabetes 

Faglia, E; Favales, F; Quarantiello, A; Nosari, I; Ghezzi, A; Et al 

1997 

Yes 

Clinical Drug Investigation
ISSN: 1173-2563 

IPA/98/1154097 

Drug Invest 

REF 53 

English 

IPA COPYRIGHT: ASHP The effects of 5-10 mg/day of amlodipine on hypertension and metabolic indices were assessed in 113 patients, ages 44-64 yr, with mild hypertension and non-insulin-dependent diabetes mellitus and compared with matched normotensive patients. Amlodipine showed notable antihypertensive effects without affecting heart rate. It had no negative effects on glucose homeostasis, beta-cell secretion, or serum lipid profile. No progression of ocular or cardiac disease was noted, indicating a possible protective effect. Eight of 82 (9.7%) treated hypertensive patients and 6 of 78 (7.7%) normotensive patients with normal urinary albumin excretion rates at baseline developed microalbuminuria after 52 wk. No patient with microalbuminuria developed proteinuria. Opposing significant intergroup differences in albumin excretion rates were noted for normotensive and hypertensive patients with baseline microalbuminuria. It was concluded that amlodipine is an effective antihypertensive agent that has no negative long term effect on glucose homeostasis, beta-cell secretion, or lipid profile, and results suggested a renoprotective role in this setting.